Wednesday, 6/25 and Thursday, 6/26 Evaluation

Question Title

* 1. Please select your designation(s):

PhD

Other (please specify)

Question Title

* 2. Please indicate your specialties:

Allergy

Asthma

Autoimmunity

Cell Biology

Dermatology

Diabetes

Endocrinology

Flow Cytometry

Gastroenterology

Genetics

Hematology

Infectious Disease

Inflammation

Microbiology

Molecular & Cellular Biology

Multiple Sclerosis

Neuroimmunology

Neurology

Oncology

Pathology

Pharmacology

Primary Immuno-deficiency

Rheumatology

Transplantation

Uveitis

Question Title

* 3. Please select the categories you most identify with:

Trainee/Fellow

Industry

Academic Faculty

Clinician

Question Title

* 4. Wednesday, June 25, 5:30-6:15 pm
Cutting Gordian Knots with the Shears of Genomics: A Quarter Century and Counting - Daniel Kastner, MD, PhD

	Disagree	Undecided	Agree	Did not Attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not Attend

Question Title

* 5. Please rate the quality of this presentation.

Excellent

Good

Average

Poor

Comments

Question Title

* 6. Did you perceive bias in this presentation?

Yes

If yes, please specify

Question Title

* 7. Thursday, June 26, 8:00-9:30 am
Robert A. Good Memorial Plenary Session: Microbe-Immune Interaction in Disease

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice as a result of what I learned in this session.	I will make changes in my practice as a result of what I learned in this session. Disagree	I will make changes in my practice as a result of what I learned in this session. Undecided	I will make changes in my practice as a result of what I learned in this session. Agree	I will make changes in my practice as a result of what I learned in this session. Did not attend

Question Title

* 8. After participating in this session, are you able to:

	Yes	No
Discuss the host and microbial mechanisms that synergize to cause/promote intestinal inflammation.	Discuss the host and microbial mechanisms that synergize to cause/promote intestinal inflammation. Yes	Discuss the host and microbial mechanisms that synergize to cause/promote intestinal inflammation. No
Describe current knowledge about the pathogenesis of atoptic dermatitis.	Describe current knowledge about the pathogenesis of atoptic dermatitis. Yes	Describe current knowledge about the pathogenesis of atoptic dermatitis. No
Discuss the role of Staphylococcus aureus in atopic dermatitis.	Discuss the role of Staphylococcus aureus in atopic dermatitis. Yes	Discuss the role of Staphylococcus aureus in atopic dermatitis. No
Elucidate the role of Staph delta toxin in allergic skin disease.	Elucidate the role of Staph delta toxin in allergic skin disease. Yes	Elucidate the role of Staph delta toxin in allergic skin disease. No
Discuss how Staph colonization may contribute to atopic dermatitis.	Discuss how Staph colonization may contribute to atopic dermatitis. Yes	Discuss how Staph colonization may contribute to atopic dermatitis. No

Question Title

* 9. Please rate the quality of the presentations:

	Excellent	Good	Average	Poor
Host-Microbial Interactions that Drive Intestinal Inflammation - Thaddeus Stappenbeck, MD, PhD	Host-Microbial Interactions that Drive Intestinal Inflammation - Thaddeus Stappenbeck, MD, PhD Excellent	Host-Microbial Interactions that Drive Intestinal Inflammation - Thaddeus Stappenbeck, MD, PhD Good	Host-Microbial Interactions that Drive Intestinal Inflammation - Thaddeus Stappenbeck, MD, PhD Average	Host-Microbial Interactions that Drive Intestinal Inflammation - Thaddeus Stappenbeck, MD, PhD Poor
Pathogen Colonization and Allergic Skin Disease - Gabriel Nunez, MD	Pathogen Colonization and Allergic Skin Disease - Gabriel Nunez, MD Excellent	Pathogen Colonization and Allergic Skin Disease - Gabriel Nunez, MD Good	Pathogen Colonization and Allergic Skin Disease - Gabriel Nunez, MD Average	Pathogen Colonization and Allergic Skin Disease - Gabriel Nunez, MD Poor
Immunomodulatory Molecules from the Microbiome - Dennis Kasper, MD	Immunomodulatory Molecules from the Microbiome - Dennis Kasper, MD Excellent	Immunomodulatory Molecules from the Microbiome - Dennis Kasper, MD Good	Immunomodulatory Molecules from the Microbiome - Dennis Kasper, MD Average	Immunomodulatory Molecules from the Microbiome - Dennis Kasper, MD Poor

Comments

Question Title

* 10. Did you perceive bias in any of the session presentations?

	Yes	No
Host-Microbial Interactions that Drive Inestinal Inflammation - Thaddeus Stappenbeck, MD, PhD	Host-Microbial Interactions that Drive Inestinal Inflammation - Thaddeus Stappenbeck, MD, PhD Yes	Host-Microbial Interactions that Drive Inestinal Inflammation - Thaddeus Stappenbeck, MD, PhD No
Pathogen Colonization and Allergic Skin Disease - Gabriel Nunez, MD	Pathogen Colonization and Allergic Skin Disease - Gabriel Nunez, MD Yes	Pathogen Colonization and Allergic Skin Disease - Gabriel Nunez, MD No
Immunomodulatory Molecules from the Microbiome - Dennis Kasper, MD	Immunomodulatory Molecules from the Microbiome - Dennis Kasper, MD Yes	Immunomodulatory Molecules from the Microbiome - Dennis Kasper, MD No

If yes, please specify

Question Title

* 11. Thursday, June 26, 10:00-11:30 am
Plenary Session: Epigenetic Control of Immune Responses

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 12. After participating in this session, are you able to:

	Yes	No
Discuss the effects of fine-mapped, noncoding genetic variants associated with human autoimmunity on immune cell-specific enhancers.	Discuss the effects of fine-mapped, noncoding genetic variants associated with human autoimmunity on immune cell-specific enhancers. Yes	Discuss the effects of fine-mapped, noncoding genetic variants associated with human autoimmunity on immune cell-specific enhancers. No

Question Title

* 13. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
Control of Gene Expression by Histone Mimics - Alexander Tarakhovsky, MD, PhD	Control of Gene Expression by Histone Mimics - Alexander Tarakhovsky, MD, PhD Excellent	Control of Gene Expression by Histone Mimics - Alexander Tarakhovsky, MD, PhD Good	Control of Gene Expression by Histone Mimics - Alexander Tarakhovsky, MD, PhD Average	Control of Gene Expression by Histone Mimics - Alexander Tarakhovsky, MD, PhD Poor
Using Dynamic Epigenetic Modifications to Analyze Transcriptional Networks Regulating Lymphocyte Activation - Harinder Singh, PhD	Using Dynamic Epigenetic Modifications to Analyze Transcriptional Networks Regulating Lymphocyte Activation - Harinder Singh, PhD Excellent	Using Dynamic Epigenetic Modifications to Analyze Transcriptional Networks Regulating Lymphocyte Activation - Harinder Singh, PhD Good	Using Dynamic Epigenetic Modifications to Analyze Transcriptional Networks Regulating Lymphocyte Activation - Harinder Singh, PhD Average	Using Dynamic Epigenetic Modifications to Analyze Transcriptional Networks Regulating Lymphocyte Activation - Harinder Singh, PhD Poor
Genetic and Epigenetic Fine-Mapping of Causal Variants in Autoimmune Disease - Alex Marson, MD, PhD	Genetic and Epigenetic Fine-Mapping of Causal Variants in Autoimmune Disease - Alex Marson, MD, PhD Excellent	Genetic and Epigenetic Fine-Mapping of Causal Variants in Autoimmune Disease - Alex Marson, MD, PhD Good	Genetic and Epigenetic Fine-Mapping of Causal Variants in Autoimmune Disease - Alex Marson, MD, PhD Average	Genetic and Epigenetic Fine-Mapping of Causal Variants in Autoimmune Disease - Alex Marson, MD, PhD Poor

Comments

Question Title

* 14. Did you perceive bias in any of the session presentations?

	Yes	No
Control of Gene Expression by Histone Mimics - Alexander Tarakhovsky, MD, PhD	Control of Gene Expression by Histone Mimics - Alexander Tarakhovsky, MD, PhD Yes	Control of Gene Expression by Histone Mimics - Alexander Tarakhovsky, MD, PhD No
Using Dynamic Epigenetic Modifications to Analyze Transcriptional Networks Regulating Lymphocyte Activation - Harinder Singh, PhD	Using Dynamic Epigenetic Modifications to Analyze Transcriptional Networks Regulating Lymphocyte Activation - Harinder Singh, PhD Yes	Using Dynamic Epigenetic Modifications to Analyze Transcriptional Networks Regulating Lymphocyte Activation - Harinder Singh, PhD No
Genetic and Epigenetic Fine-Mapping of Causal Variants in Autoimmune Disease - Alex Marson, MD, PhD	Genetic and Epigenetic Fine-Mapping of Causal Variants in Autoimmune Disease - Alex Marson, MD, PhD Yes	Genetic and Epigenetic Fine-Mapping of Causal Variants in Autoimmune Disease - Alex Marson, MD, PhD No

If yes, please specify

Question Title

* 15. Thursday, June 26, 1:00-2:45 pm
Concurrent Thematic Symposium: Humanized Mice for Studying Immune Disorders

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 16. After participating in this session, are you able to:

	Yes	No
Discuss humanized mice models.	Discuss humanized mice models. Yes	Discuss humanized mice models. No
Describe the various models of establishing human immune systems in immunodeficient mice.	Describe the various models of establishing human immune systems in immunodeficient mice. Yes	Describe the various models of establishing human immune systems in immunodeficient mice. No
Discuss barriers to creating an individualized human immune system in mice.	Discuss barriers to creating an individualized human immune system in mice. Yes	Discuss barriers to creating an individualized human immune system in mice. No
Describe methods of overcoming barriers to creating individualized human immune system in mice.	Describe methods of overcoming barriers to creating individualized human immune system in mice. Yes	Describe methods of overcoming barriers to creating individualized human immune system in mice. No

Question Title

* 17. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
Humanized Mice in Immunity, Development and Disease - Richard Flavell, PhD	Humanized Mice in Immunity, Development and Disease - Richard Flavell, PhD Excellent	Humanized Mice in Immunity, Development and Disease - Richard Flavell, PhD Good	Humanized Mice in Immunity, Development and Disease - Richard Flavell, PhD Average	Humanized Mice in Immunity, Development and Disease - Richard Flavell, PhD Poor
Humanized Mice for the Study of Human Immunity - Dale Greiner, PhD	Humanized Mice for the Study of Human Immunity - Dale Greiner, PhD Excellent	Humanized Mice for the Study of Human Immunity - Dale Greiner, PhD Good	Humanized Mice for the Study of Human Immunity - Dale Greiner, PhD Average	Humanized Mice for the Study of Human Immunity - Dale Greiner, PhD Poor
Personalized Immune Mice - Megan Sykes, MD	Personalized Immune Mice - Megan Sykes, MD Excellent	Personalized Immune Mice - Megan Sykes, MD Good	Personalized Immune Mice - Megan Sykes, MD Average	Personalized Immune Mice - Megan Sykes, MD Poor

Comments

Question Title

* 18. Did you perceive bias in any of the session presentations?

	Yes	No
Humanized Mice in Immunity, Development and Disease - Richard Flavell, PhD	Humanized Mice in Immunity, Development and Disease - Richard Flavell, PhD Yes	Humanized Mice in Immunity, Development and Disease - Richard Flavell, PhD No
Humanized Mice for the Study of Human Immunity - Dale Greiner, PhD	Humanized Mice for the Study of Human Immunity - Dale Greiner, PhD Yes	Humanized Mice for the Study of Human Immunity - Dale Greiner, PhD No
Personalized Immune Mice - Megan Sykes, MD	Personalized Immune Mice - Megan Sykes, MD Yes	Personalized Immune Mice - Megan Sykes, MD No

If yes, please specify

Question Title

* 19. Thursday, June 26, 1:00-2:45 pm
Concurrent Thematic Symposium: Manipulating DCs for Tolerance or Rejection

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 20. After participating in this session, are you able to:

	Yes	No
Discuss current treatments for autoimmune diseases.	Discuss current treatments for autoimmune diseases. Yes	Discuss current treatments for autoimmune diseases. No
Describe why antigen-specific immunotherapy is the holy grail for immunotherapy of autoimmune diseases.	Describe why antigen-specific immunotherapy is the holy grail for immunotherapy of autoimmune diseases. Yes	Describe why antigen-specific immunotherapy is the holy grail for immunotherapy of autoimmune diseases. No
Discuss how dendritic cells are composed of functionally different subsets.	Discuss how dendritic cells are composed of functionally different subsets. Yes	Discuss how dendritic cells are composed of functionally different subsets. No
Describe how Follicular helper T cells are controlled by different subsets which differentially activate T cells.	Describe how Follicular helper T cells are controlled by different subsets which differentially activate T cells. Yes	Describe how Follicular helper T cells are controlled by different subsets which differentially activate T cells. No
Describe how the interplay between these different cell types will result in better design of the next-generation vaccines.	Describe how the interplay between these different cell types will result in better design of the next-generation vaccines. Yes	Describe how the interplay between these different cell types will result in better design of the next-generation vaccines. No

Question Title

* 21. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
Antigen-Specific Immunotherapy for Multiple Sclerosis - David Wraith, PhD	Antigen-Specific Immunotherapy for Multiple Sclerosis - David Wraith, PhD Excellent	Antigen-Specific Immunotherapy for Multiple Sclerosis - David Wraith, PhD Good	Antigen-Specific Immunotherapy for Multiple Sclerosis - David Wraith, PhD Average	Antigen-Specific Immunotherapy for Multiple Sclerosis - David Wraith, PhD Poor
Improving Vaccines by Harnessing Dendritic Cell Subsets and T Cell Subsets - Jacques Banchereau, PhD	Improving Vaccines by Harnessing Dendritic Cell Subsets and T Cell Subsets - Jacques Banchereau, PhD Excellent	Improving Vaccines by Harnessing Dendritic Cell Subsets and T Cell Subsets - Jacques Banchereau, PhD Good	Improving Vaccines by Harnessing Dendritic Cell Subsets and T Cell Subsets - Jacques Banchereau, PhD Average	Improving Vaccines by Harnessing Dendritic Cell Subsets and T Cell Subsets - Jacques Banchereau, PhD Poor

Comments

Question Title

* 22. Did you perceive bias in any of the session presentations?

	Yes	No
Antigen-Specific Immunotherapy for Multiple Sclerosis - David Wraith, PhD	Antigen-Specific Immunotherapy for Multiple Sclerosis - David Wraith, PhD Yes	Antigen-Specific Immunotherapy for Multiple Sclerosis - David Wraith, PhD No
Improving Vaccines by Harnessing Dendritic Cell Subsets and T Cell Subsets - Jacques Banchereau, PhD	Improving Vaccines by Harnessing Dendritic Cell Subsets and T Cell Subsets - Jacques Banchereau, PhD Yes	Improving Vaccines by Harnessing Dendritic Cell Subsets and T Cell Subsets - Jacques Banchereau, PhD No

If yes, please specify

Question Title

* 23. Thursday, June 26, 1:00-2:45 pm
Concurrent Thematic Symposium: The Ups and Downs of IL-2

	Disagree	Undecided	Agree	Did not attend
I will make changes to my practice/profession as a result of what I learned in this session.	I will make changes to my practice/profession as a result of what I learned in this session. Disagree	I will make changes to my practice/profession as a result of what I learned in this session. Undecided	I will make changes to my practice/profession as a result of what I learned in this session. Agree	I will make changes to my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 24. After participating in this session, are you able to:

	Yes	No
Discuss the effects of IL-2 treatment on Treg stability.	Discuss the effects of IL-2 treatment on Treg stability. Yes	Discuss the effects of IL-2 treatment on Treg stability. No
Describe the additional effects of IL-2 on innate lymphoid cells.	Describe the additional effects of IL-2 on innate lymphoid cells. Yes	Describe the additional effects of IL-2 on innate lymphoid cells. No
Discuss the role of interleukin-2 (IL-2) in immune tolerance and in stimulating effector lymphocytes, eosinophilia and unwanted immunity.	Discuss the role of interleukin-2 (IL-2) in immune tolerance and in stimulating effector lymphocytes, eosinophilia and unwanted immunity. Yes	Discuss the role of interleukin-2 (IL-2) in immune tolerance and in stimulating effector lymphocytes, eosinophilia and unwanted immunity. No
Discuss approaches to harness the potential of IL-2 for selective immunotherapy aimed at restoring immune tolerance mechanisms in inflammation, autoimmunity and graft rejection.	Discuss approaches to harness the potential of IL-2 for selective immunotherapy aimed at restoring immune tolerance mechanisms in inflammation, autoimmunity and graft rejection. Yes	Discuss approaches to harness the potential of IL-2 for selective immunotherapy aimed at restoring immune tolerance mechanisms in inflammation, autoimmunity and graft rejection. No
Describe another type of IL-2 immunotherapy targeted at stimulation of effector lymphocytes against metastatic cancer.	Describe another type of IL-2 immunotherapy targeted at stimulation of effector lymphocytes against metastatic cancer. Yes	Describe another type of IL-2 immunotherapy targeted at stimulation of effector lymphocytes against metastatic cancer. No

Question Title

* 25. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
Immunoregulation Without Immunosuppression: The Promise of Low Dose IL-2 - David Klatzmann, MD, PhD	Immunoregulation Without Immunosuppression: The Promise of Low Dose IL-2 - David Klatzmann, MD, PhD Excellent	Immunoregulation Without Immunosuppression: The Promise of Low Dose IL-2 - David Klatzmann, MD, PhD Good	Immunoregulation Without Immunosuppression: The Promise of Low Dose IL-2 - David Klatzmann, MD, PhD Average	Immunoregulation Without Immunosuppression: The Promise of Low Dose IL-2 - David Klatzmann, MD, PhD Poor
Effects of IL-2 Therapy on Treg Stability and Other Immune Cell Types - Jeff Bluestone, PhD	Effects of IL-2 Therapy on Treg Stability and Other Immune Cell Types - Jeff Bluestone, PhD Excellent	Effects of IL-2 Therapy on Treg Stability and Other Immune Cell Types - Jeff Bluestone, PhD Good	Effects of IL-2 Therapy on Treg Stability and Other Immune Cell Types - Jeff Bluestone, PhD Average	Effects of IL-2 Therapy on Treg Stability and Other Immune Cell Types - Jeff Bluestone, PhD Poor
Selective Immunotherapy Using Interleukin-2 Formations - Onur Boyman, MD	Selective Immunotherapy Using Interleukin-2 Formations - Onur Boyman, MD Excellent	Selective Immunotherapy Using Interleukin-2 Formations - Onur Boyman, MD Good	Selective Immunotherapy Using Interleukin-2 Formations - Onur Boyman, MD Average	Selective Immunotherapy Using Interleukin-2 Formations - Onur Boyman, MD Poor

Comments

Question Title

* 26. Did you perceive bias in any of the session presentations?

	Yes	No
Immunoregulation Without Immunosuppression: The Promise of Low Dose IL-2 - David Klatzmann, MD, PhD	Immunoregulation Without Immunosuppression: The Promise of Low Dose IL-2 - David Klatzmann, MD, PhD Yes	Immunoregulation Without Immunosuppression: The Promise of Low Dose IL-2 - David Klatzmann, MD, PhD No
Effects of IL-2 Therapy on Treg Stability and Other Immune Cell Types - Jeff Bluestone, PhD	Effects of IL-2 Therapy on Treg Stability and Other Immune Cell Types - Jeff Bluestone, PhD Yes	Effects of IL-2 Therapy on Treg Stability and Other Immune Cell Types - Jeff Bluestone, PhD No
Selective Immunotherapy Using Interleukin-2 Formations - Onur Boyman, MD	Selective Immunotherapy Using Interleukin-2 Formations - Onur Boyman, MD Yes	Selective Immunotherapy Using Interleukin-2 Formations - Onur Boyman, MD No

If yes, please specify

Question Title

* 27. Thursday, June 26, 3:15-5:15 pm
Principles of Flow Cytometry for Immune Monitoring Course: RNA Detection by Flow Cytometry

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 28. After participating in this session, are you able to:

	Yes	No
Describe the methods enabling RNA detection by flow cytometry.	Describe the methods enabling RNA detection by flow cytometry. Yes	Describe the methods enabling RNA detection by flow cytometry. No
Discuss the universal method for RNA preservation in fixed and permeabilized cells.	Discuss the universal method for RNA preservation in fixed and permeabilized cells. Yes	Discuss the universal method for RNA preservation in fixed and permeabilized cells. No
Describe DNA-based co-detection of RNA and proteins by flow cytometry.	Describe DNA-based co-detection of RNA and proteins by flow cytometry. Yes	Describe DNA-based co-detection of RNA and proteins by flow cytometry. No
Describe the association between telomeres and the proliferative capacity of T cells.	Describe the association between telomeres and the proliferative capacity of T cells. Yes	Describe the association between telomeres and the proliferative capacity of T cells. No
Discuss how telomerase maintains telomere length.	Discuss how telomerase maintains telomere length. Yes	Discuss how telomerase maintains telomere length. No
Describe how telemere length can be measured in leukoicytes by multicolor flow cytometry.	Describe how telemere length can be measured in leukoicytes by multicolor flow cytometry. Yes	Describe how telemere length can be measured in leukoicytes by multicolor flow cytometry. No

Question Title

* 29. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
RNA Based Single-Cell Mapping of Hematopoiesis - Yury Goltsev, PhD	RNA Based Single-Cell Mapping of Hematopoiesis - Yury Goltsev, PhD Excellent	RNA Based Single-Cell Mapping of Hematopoiesis - Yury Goltsev, PhD Good	RNA Based Single-Cell Mapping of Hematopoiesis - Yury Goltsev, PhD Average	RNA Based Single-Cell Mapping of Hematopoiesis - Yury Goltsev, PhD Poor
The Regulation of Telomere Erosion in Memory T Cells After Immune Challenge in vivo - Arne Akbar, PhD	The Regulation of Telomere Erosion in Memory T Cells After Immune Challenge in vivo - Arne Akbar, PhD Excellent	The Regulation of Telomere Erosion in Memory T Cells After Immune Challenge in vivo - Arne Akbar, PhD Good	The Regulation of Telomere Erosion in Memory T Cells After Immune Challenge in vivo - Arne Akbar, PhD Average	The Regulation of Telomere Erosion in Memory T Cells After Immune Challenge in vivo - Arne Akbar, PhD Poor

Comments

Question Title

* 30. Did you perceive bias in any of the session presentations?

	Yes	No
RNA Based Single-Cell Mapping of Hematopoiesis - Yury Goltsev, PhD	RNA Based Single-Cell Mapping of Hematopoiesis - Yury Goltsev, PhD Yes	RNA Based Single-Cell Mapping of Hematopoiesis - Yury Goltsev, PhD No
The Regulation of Telomere Erosion in Memory T Cells After Immune Challenge in vivo - Arne Akbar, PhD	The Regulation of Telomere Erosion in Memory T Cells After Immune Challenge in vivo - Arne Akbar, PhD Yes	The Regulation of Telomere Erosion in Memory T Cells After Immune Challenge in vivo - Arne Akbar, PhD No

If yes, please specify

Question Title

* 31. Thursday, June 26, 5:30-6:15 pm
Keynote Address: Immune Memory to Viruses - Rafi Ahmed, PhD

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 32. Please rate the quality of this presentation.

Excellent

Good

Average

Poor

Comments

Question Title

* 33. Did you perceive bias in this presentation?

Yes

If yes, please specify

Question Title

* 34. If you would like to receive a CME certificate or certificate of attendance, please indicate below.

CME Certificate

Certificate of Attendance

Please enter your email to receive a certificate

Question Title

* 1. Please select your designation(s):

Question Title

* 2. Please indicate your specialties:

Question Title

* 3. Please select the categories you most identify with:

Question Title

* 4. Wednesday, June 25, 5:30-6:15 pmCutting Gordian Knots with the Shears of Genomics: A Quarter Century and Counting - Daniel Kastner, MD, PhD

Question Title

* 5. Please rate the quality of this presentation.

Question Title

* 6. Did you perceive bias in this presentation?

Question Title

* 7. Thursday, June 26, 8:00-9:30 am Robert A. Good Memorial Plenary Session: Microbe-Immune Interaction in Disease

Question Title

* 8. After participating in this session, are you able to:

Question Title

* 9. Please rate the quality of the presentations:

Question Title

* 10. Did you perceive bias in any of the session presentations?

Question Title

* 11. Thursday, June 26, 10:00-11:30 am Plenary Session: Epigenetic Control of Immune Responses

Question Title

* 12. After participating in this session, are you able to:

Question Title

* 13. Please rate the quality of the session presentations:

Question Title

* 14. Did you perceive bias in any of the session presentations?

Question Title

* 15. Thursday, June 26, 1:00-2:45 pmConcurrent Thematic Symposium: Humanized Mice for Studying Immune Disorders

Question Title

* 16. After participating in this session, are you able to:

Question Title

* 17. Please rate the quality of the session presentations:

Question Title

* 18. Did you perceive bias in any of the session presentations?

Question Title

* 19. Thursday, June 26, 1:00-2:45 pmConcurrent Thematic Symposium: Manipulating DCs for Tolerance or Rejection

Question Title

* 20. After participating in this session, are you able to:

Question Title

* 21. Please rate the quality of the session presentations:

Question Title

* 22. Did you perceive bias in any of the session presentations?

Question Title

* 23. Thursday, June 26, 1:00-2:45 pmConcurrent Thematic Symposium: The Ups and Downs of IL-2

Question Title

* 24. After participating in this session, are you able to:

Question Title

* 25. Please rate the quality of the session presentations:

Question Title

* 26. Did you perceive bias in any of the session presentations?

Question Title

* 27. Thursday, June 26, 3:15-5:15 pmPrinciples of Flow Cytometry for Immune Monitoring Course: RNA Detection by Flow Cytometry

Question Title

* 28. After participating in this session, are you able to:

Question Title

* 29. Please rate the quality of the session presentations:

Question Title

* 30. Did you perceive bias in any of the session presentations?

Question Title

* 31. Thursday, June 26, 5:30-6:15 pm Keynote Address: Immune Memory to Viruses - Rafi Ahmed, PhD

Question Title

* 32. Please rate the quality of this presentation.

Question Title

* 33. Did you perceive bias in this presentation?

Question Title

* 34. If you would like to receive a CME certificate or certificate of attendance, please indicate below.

* 4. Wednesday, June 25, 5:30-6:15 pm
Cutting Gordian Knots with the Shears of Genomics: A Quarter Century and Counting - Daniel Kastner, MD, PhD

* 7. Thursday, June 26, 8:00-9:30 am
Robert A. Good Memorial Plenary Session: Microbe-Immune Interaction in Disease

* 11. Thursday, June 26, 10:00-11:30 am
Plenary Session: Epigenetic Control of Immune Responses

* 15. Thursday, June 26, 1:00-2:45 pm
Concurrent Thematic Symposium: Humanized Mice for Studying Immune Disorders

* 19. Thursday, June 26, 1:00-2:45 pm
Concurrent Thematic Symposium: Manipulating DCs for Tolerance or Rejection

* 23. Thursday, June 26, 1:00-2:45 pm
Concurrent Thematic Symposium: The Ups and Downs of IL-2

* 27. Thursday, June 26, 3:15-5:15 pm
Principles of Flow Cytometry for Immune Monitoring Course: RNA Detection by Flow Cytometry

* 31. Thursday, June 26, 5:30-6:15 pm
Keynote Address: Immune Memory to Viruses - Rafi Ahmed, PhD